Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 89,258,656
  • Shares Outstanding, K 1,253,809
  • Annual Sales, $ 24,689 M
  • Annual Income, $ 123,000 K
  • 60-Month Beta 0.39
  • Price/Sales 3.64
  • Price/Cash Flow 8.64
  • Price/Book 4.58
Trade GILD with:

Options Overview Details

View History
  • Implied Volatility 22.00%
  • Historical Volatility 15.02%
  • IV Percentile 19%
  • IV Rank 23.66%
  • IV High 40.33% on 01/04/21
  • IV Low 16.32% on 09/08/21
  • Put/Call Vol Ratio 0.42
  • Today's Volume 26,601
  • Volume Avg (30-Day) 18,798
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 356,585
  • Open Int (30-Day) 390,163

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 1.65
  • Number of Estimates 9
  • High Estimate 1.72
  • Low Estimate 1.47
  • Prior Year 2.11
  • Growth Rate Est. (year over year) -21.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
70.11 +1.54%
on 09/14/21
72.83 -2.25%
on 08/31/21
-1.06 (-1.47%)
since 08/24/21
3-Month
66.88 +6.44%
on 06/25/21
73.34 -2.93%
on 08/18/21
+4.01 (+5.97%)
since 06/24/21
52-Week
56.56 +25.87%
on 12/31/20
73.34 -2.93%
on 08/18/21
+8.94 (+14.36%)
since 09/24/20

Most Recent Stories

More News
Antiretroviral Drugs Market: Industry Insights By Growth, Emerging Trends And Forecast By 2028

Research Nester has published a report titled "which delivers detailed overview of the antiretroviral drugs market in terms of market segmentation by drug type and by region.

GILD : 71.19 (-0.70%)
GSK : 38.39 (-2.41%)
BMY : 60.23 (-0.66%)
ABT : 124.37 (-0.74%)
AZN.LN : 8,845.000 (+2.04%)
MRK : 73.61 (+0.77%)
JNJ : 164.36 (-0.30%)
NOVN : 8.14 (-3.78%)
AbCellera (ABCL), Everest to Co-Develop New Antibody Therapies

AbCellera (ABCL) partners with China-based Everest Medicines to expand the latter???s pipeline across multiple indications.

REGN : 638.90 (-1.18%)
LLY : 231.68 (-0.22%)
GILD : 71.19 (-0.70%)
ABCL : 21.15 (unch)
Leukemia Therapeutics Market Top Companies, Business Growth & Investment Opportunities, Share and Forecasts to 2028

Research Nester has released a report titled " - Global Demand Analysis & Opportunity Outlook 2028" which also includes some of the prominent market analyzing parameters such as industry growth drivers,...

AMGN : 213.61 (-0.67%)
AZN.LN : 8,845.000 (+2.04%)
NOVN : 8.14 (-3.78%)
ABBV : 107.07 (-0.27%)
SAN : 3.64 (+0.28%)
GILD : 71.19 (-0.70%)
Veklury(R) (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19

--- Late-breaking Data to be Presented at IDWeek 2021 -

GILD : 71.19 (-0.70%)
3 Value Stocks to Buy While You Still Can

After outperforming from last fall into the spring, value stocks have been overtaken by growth stocks, but that is expected to change as the economic recovery continues. So, now is the time to start putting...

GILD : 71.19 (-0.70%)
HPQ : 27.89 (-0.32%)
CNHI : 17.09 (-0.81%)
Gilead Sciences (GILD) Stock Moves -0.91%: What You Should Know

Gilead Sciences (GILD) closed at $70.96 in the latest trading session, marking a -0.91% move from the prior day.

GILD : 71.19 (-0.70%)
Global Immunotherapy Drugs Market Report Analysis, Share, Revenue, Growth Rate With Forecast Overview 2029

Research Nester published a report titled which delivers detailed overview of the global immunotherapy drugs market in terms of market segmentation by type, therapy area, and by region.

MRK : 73.61 (+0.77%)
GILD : 71.19 (-0.70%)
PFE : 43.94 (-0.57%)
AZN : 60.35 (+1.46%)
BMY : 60.23 (-0.66%)
GSK : 38.39 (-2.41%)
RHHBY : 46.0100 (-0.88%)
NVS : 82.93 (-0.77%)
BAYRY : 13.7100 (-0.22%)
Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021

--- Research Examines Strategies to Enhance the Participation of Communities Underrepresented in HIV Clinical Trials -

GILD : 71.19 (-0.70%)
Global Diverticulitis Drugs Market Increasing Gastrointestinal Diseases to Create Growth Opportunities for the Market till 2029

Research Nester published a report titled "" which delivers detailed overview of the global diverticulitis drugs market in terms of market segmentation by drug type, route of administration, distribution...

EMMA : 1.7000 (unch)
ABT : 124.37 (-0.74%)
GSK : 38.39 (-2.41%)
ARDX : 1.3100 (-2.96%)
GILD : 71.19 (-0.70%)
PFE : 43.94 (-0.57%)
HIK.LN : 2,386.000 (+0.89%)
Lymphoproliferative Disorder Treatment Market Emerging Trends, Market Research, And Comprehensive Insights 2028

Research Nester released a report titled "" which delivers detailed overview of the global lymphoproliferative disorder treatment market in terms of market segmentation by route of administration, drug...

ATRA : 17.00 (-1.73%)
NOVN : 8.14 (-3.78%)
MRK : 73.61 (+0.77%)
BMY : 60.23 (-0.66%)
ABBV : 107.07 (-0.27%)
GILD : 71.19 (-0.70%)
AZN.LN : 8,845.000 (+2.04%)
PFE : 43.94 (-0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

3rd Resistance Point 72.34
2nd Resistance Point 72.10
1st Resistance Point 71.65
Last Price 71.19
1st Support Level 70.96
2nd Support Level 70.72
3rd Support Level 70.27

See More

52-Week High 73.34
Last Price 71.19
Fibonacci 61.8% 66.93
Fibonacci 50% 64.95
Fibonacci 38.2% 62.97
52-Week Low 56.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar